Sosei Buys Heptares To Secure New Drug Creation Platform, Early Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquiring Heptares brings Sosei a cutting edge GPCR drug discovery platform and lucrative on-going alliances, and a much needed strategy to grow beyond royalties from Ultibro Breezhaler and Seebri Breezhaler, whose patents expire in 2016.